Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 105kWORD 18k
15 January 2018
Answer given by Mr Andriukaitis on behalf of the Commission
Question reference: E-007105/2017

According to the ‘Health at a Glance: Europe 2016 — State of Health in the EU Cycle’ cancer is the second leading cause of mortality in EU Member States after cardiovascular diseases.

Lung cancer is the most common cause of death from cancer among men and the second cause of death from cancer among women.

It is estimated that smoking is responsible for about 85% of all instances of lung cancer. The Commission has adopted a number of tobacco control measures intended to protect citizens from the hazardous effects of smoking, including by deterring the initiation of tobacco consumption, particularly as regards young people, and by limiting exposure to second-hand smoke(1).

The Commission can help Member States by funding initiatives and projects to promote smoke-free policies and healthy life styles, and providing Member States with EU best practices and guidelines to be implemented at national level in the areas of cancer screening, quality assurance in cancer management, integrated cancer control, after-care at community level, and survivorship and rehabilitation(2).

Moreover, considering the need for a cross-sector and integrated approach to reduce the high mortality rate due to lung cancer, the Country Health Profiles recently published by the Commission will help to provide a better evidence base to ensure that all EU citizens have access to effective cancer care through implementation of innovative, safe, and effective patient centred cancer planning(3).

In addition, the clinical trials Regulation(4), which will become applicable in 2019, will make it easier to conduct multinational clinical trials in Europe increasing innovation and facilitating participation in clinical trials.


Last updated: 8 June 2018Legal notice